ArticleAmerican journal of cardiovascular disease2020
Severe mitral valve regurgitation secondary to Libman-Sacks endocarditis.
Article in American journal of cardiovascular disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although uncommon, Libman-Sack endocarditis is the most characteristic cardiac manifestation of Systemic Lupus Erythematosus (SLE). It forms vegetations made of inflammatory tissue on the cardiac valves, leading them to malfunction. Here we present a case of a young woman who presented with severe mitral valve regurgitation in need for a valve replacement. Integral evaluation of the patient revealed the diagnosis of SLE, which was aggressively treated in an outpatient setting with immunosuppressive therapy. Only after achieving medical stabilization of the underlying disease, she was able to undergo surgical mitral valve replacement. After the surgery, the patient no longer suffered from mitral regurgitation, and with a mechanical prosthesis in place, the risk of Libman-Sacks endocarditis recurrence is thought to be minimal.
Indexed as
Identifiers
33224587PMC7675162W3108793919What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.